Two additional SCLC targets in clinical development are delta-like ligand 3 (DLL3), an inhibitor of Notch 1 ligand and B7H3 (CD276), an immunoregulatory protein member of the B7 family. Here, NOTCH1 is linked to small cell lung carcinoma.